MARKET

TLIS

TLIS

Talis Biomedical Corp
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.04
-0.26
-3.56%
After Hours: 7.04 0 0.00% 16:00 09/24 EDT
OPEN
7.18
PREV CLOSE
7.30
HIGH
7.20
LOW
6.98
VOLUME
105.17K
TURNOVER
--
52 WEEK HIGH
33.90
52 WEEK LOW
6.81
MARKET CAP
149.11M
P/E (TTM)
-1.1459
1D
5D
1M
3M
1Y
5Y
ACST, AMSC and NETE among mid-day movers
Gainers: Regional Health Properties (NYSE:RHE) +55%. AC Immune (NASDAQ:ACIU) +34%. Net Element (NASDAQ:NETE) +27%. Vallon Pharmaceuticals (NASDAQ:VLON) +25%. Spok (NASDAQ:SPOK) +23%. Elys Game Technology (NASDAQ:ELYS) +21%. Youdao (NYSE:DAO) +20%. Qualigen
Seekingalpha · 08/31 16:54
33 Stocks Moving In Tuesday's Mid-Day Session
Gainers
Benzinga · 08/31 16:05
Regional Health Properties, AC Immune leads healthcare gainers; RenovoRx, Poseida Therapeutics among major losers
Gainers: Regional Health Properties (NYSE:RHE) +53%, AC Immune (NASDAQ:ACIU) +39%, Regencell Bioscience (NASDAQ:RGC) +29%, Qualigen Therapeutics (NASDAQ:QLGN) +19%, Reneo Pharmaceuticals (NASDAQ:RPHM) +17%. Losers: RenovoRx (NASDAQ:RNXT) -21%, Poseida Ther...
Seekingalpha · 08/31 15:11
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26)
Benzinga · 08/31 12:05
Talis Biomedical CEO Brian Coe Steps Down; Kim Popovits to Serve as Interim CEO
MT Newswires · 08/30 17:00
Stocks That Hit 52-Week Lows On Friday
    Friday morning, 94 companies reached new 52-week lows.
Benzinga · 08/13 14:13
Piper Sandler Downgrades Talis Biomedical to Neutral, Announces $9 Price Target
Piper Sandler analyst Steven Mah downgrades Talis Biomedical (NASDAQ:TLIS) from Overweight to Neutral and announces $9 price target.
Benzinga · 08/12 09:08
--Piper Sandler Downgrades Talis Biomedical to Neutral From Overweight; Price Target is $9
MT Newswires · 08/12 06:09
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TLIS. Analyze the recent business situations of Talis Biomedical Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TLIS stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 43
Institutional Holdings: 19.58M
% Owned: 92.45%
Shares Outstanding: 21.18M
TypeInstitutionsShares
Increased
12
800.64K
New
7
151.94K
Decreased
17
1.57M
Sold Out
7
718.73K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chief Executive Officer
Kimberly Popovits
Co-Founder/Director
Rustem Ismagilov
Chief Financial Officer
J. Roger Moody
Senior Vice President
Karen Flick
Senior Vice President
Douglas Liu
Senior Vice President
Ramesh Ramakrishnan
Other
Robert Kelley
Director
Felix Baker
Director
Raymond Cheong
Independent Director
Melissa Gilliam
Independent Director
Jeryl Hilleman
Independent Director
Matthew Posard
Independent Director
Randal Scott
No Data
About TLIS
Talis Biomedical Corporation. (Talis) Is engaged in developing molecular diagnostic tests for infectious diseases at the point of care. The Company is focused on developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions. Talis is developing the Talis One platform, a cloud-enabled molecular diagnostic platform. The Talis One platform comprises a compact instrument, single-use test cartridges and software, including a central cloud database, which work together and are designed to provide central laboratory levels of accuracy. The platform is designed for use in non-laboratory settings, such as physicians’ offices, hospital emergency departments, urgent care clinics, ambulatory surgery centers, assisted living facilities, and cancer treatment and dialysis centers. The Company is also developing Talis One tests for respiratory infections, infections related to women’s health and sexually transmitted infections.

Webull offers kinds of Talis Biomedical Corp stock information, including NASDAQ:TLIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLIS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TLIS stock methods without spending real money on the virtual paper trading platform.